Table 5.
Differences in breastfeeding and non-breastfeeding mothers with SLE 12 months after delivery
| N |
Breastfeeding N = 27 |
N |
Non-breastfeeding N = 63 |
p-valuea | |
|---|---|---|---|---|---|
| Age ≥ 35 years, (%) | 27 | 22.2 | 63 | 28.6 | 0.61 |
| BMI (kg/m2), mean (SD) | 25 | 24.5 (4.0) | 40 | 23.9 (5.1) | 0.34 |
| Overweight (≥ 25 kg/m2), (%) | 25 | 44.0 | 40 | 33.3 | 0.43 |
| Working status (full- or parttime), (%) | 27 | 40.7 | 45 | 48.9 | 0.63 |
| VAS scores (0–100), median (IQR) | 23 | 33 | |||
| Pain | 15 (1–61) | 18 (4–26) | 0.57 | ||
| Fatigue | 33 (7–73) | 30(10–51) | 0.75 | ||
| Global score | 13 (1–24) | 25 (10–41) | 0.06 | ||
| Inflammatory active disease* (%) | 21 | 9.5 | 28 | 21.4 | 0.44 |
| CRP value (mg/L), mean (SD) | 26 | 2.50 (4.5) | 42 | 2.48 (3.1) | 0.18 |
| Regular physical activity** (%) | 18 | 38.9 | 32 | 53.1 | 0.39 |
| Medications, n (%) | 27 | 63 | |||
| HCQ | 22 (81.5) | 45 (71.4) | 0.43 | ||
| sDMARD*** | 10 (37.0) | 20 (31.7) | 0.63 | ||
| bDMARD**** | 0 | 1 (1.6) | - |
SD standard deviation, BMI bodymass index, CRP c-reactive protein, VAS visual analog scale, IQR interquartile range, HCQ hydroxychloroquine, s-DMARD synthetic disease modifying anti-rheumatic drugs, bDMARDs biologic disease modifying anti-rheumatic drugs
*measured by LAI-P/SLEDAI. Active disease: ≥ 2,2 (LAI-P) or > 6 (SLEDAI)
**at least once weekly
***sDMARDs included azathioprine, methotrexate, sulphasalazine and mycophenolate mofetil
****bDMARDs included belimumab, TNF-inhibitors and interleukin inhibitors
agroup comparisons were performed using Fisher´s exact test for categorical variables and independent samples t-test for continuous, normally distributed variables. For ordinal and continuous, non-normally distributed data Mann Whitney U test was performed